Dova Pharma

Dova Pharmaceuticals a clinical-stage pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet medical need. With a nimble approach and a team of bright minds aglow with passion, we’re dedicated to bringing brilliant medicine to market.

SNOHOMISH, Wash.--(BUSINESS WIRE)-- #antimalware--Cyemptive Technologies Names Former Branch Chief for Cyber Policy and Capabilities at The Joint Chiefs of Staff as Vice President of Security.

Cyemptive Technologies Names Former Branch Chief for Cyber Policy and Capabilities at The Joint Chiefs of Staff Retired US Navy Commander Vince Dova as Vice President of Security

DURHAM, N.C.--(BUSINESS WIRE)--Istari Oncology, Inc., a clinical-stage biotechnology company today announced that Marc Banjak has joined the company as general counsel and secretary. Mr. Banjak comes to Istari from Dova Pharmaceuticals (NASDAQ: DOVA), where he led the legal and compliance teams. While at Dova, he helped guide the company's lead product through two regulatory approvals by the US Food and Drug Administration for the treatment of thrombocytopenia. In addition to FDA milestones, he

Istari Oncology Hires Marc Banjak as General Counsel and Secretary as the Company Prepares for a Critical Period of Development and Expansion

DURHAM, N.C., Dec. 1, 2020 /PRNewswire/ -- Dova Pharmaceuticals, Inc., a wholly-owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), today announced that data on DOPTELET® (avatrombopag), an oral thrombopoietin receptor agonist (TPO-RA) for the treatment of chronic immune...

Dova Announces DOPTELET® (avatrombopag) Data Presentations at Upcoming 62nd American Society of Hematology Annual Meeting and Exposition

Amgen

GlaxoSmithKline

Dova combined with Sobi spells threat for a part of the business for Amgen and GlaxoSmithKline.

Sobi + Dova: A Threat For Amgen And GlaxoSmithKline

Dova Pharmaceuticals (DOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Dova Pharmaceuticals (DOVA) Report Negative Q3 Earnings? What You Should Know

Dova Pharmaceuticals has moved higher as of late, but there could definitely be trouble on the horizon for this company.

Dova Pharmaceuticals Enters Overbought Territory: Is A Drop Coming?

Why Shares of Dova Pharmaceuticals Took Off in September

Bed Bath & Beyond

Thor Industries

Earnings and other good news helped these stocks climb.

Why Thor Industries, Dova Pharmaceuticals, and Bed Bath & Beyond Jumped Today

Dova Pharmaceuticals (DOVA) news for Monday about a $915 million deal with Swedish Orphan Biovitrum has DOVA stock flying high.
The post Dova Pharmaceuticals News: DOVA Stock Skyrockets 38% on Sobi Deal appeared first on InvestorPlace.

Dova Pharmaceuticals News: DOVA Stock Skyrockets 38% on Sobi Deal

Stockholm-based Sobi wants to expand its U.S. presence, beginning with Dova's platelet therapy.

Here's Why Dova Pharmaceuticals Stock Is Rocketing Higher Today

On Monday, Dova announced a $915 million plan to merge with Swedish Orphan Biovitrum — sending Dova stock into the stratosphere. The deal is at a 36% premium to Dova's closing price Friday.

Biotech Stock Gets $915 Million Takeover Deal — And Rockets 39%

Dova Pharmaceuticals Inc. (NASDAQ: DOVA) shares jumped on Monday after the firm announced that it would be acquired by Swedish Orphan Biovitrum, or Sobi.

Are Dova Pharma Investors Getting the Most Out of This Acquisition?

Shares of small-cap biotech Dova Pharmaceuticals Inc (NASDAQ: DOVA) were advancing strongly Monday in reaction to a buyout deal.

Dova Pharmaceuticals Rallies Following Deal To Be Acquired By SOBI For Up To $915M

Dova Pharmaceuticals DOVA, -0.02% shares climbed 37% to $27.75 a share in premarket trade after Swedish Orphan Biovitrum SOBI, +2.88% said it will buy the company for $27.50 a share in cash, plus an additional $1.50 a share if the Food and Drug Administration approves Doptelet for use in chemotherapy-induced thrombocytopenia.

Dova Pharmaceuticals rallies on buyout offer from Swedish Orphan Biovitrum

DURHAM, N.C., Sept.  30, 2019  (GLOBE NEWSWIRE) --  Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) announced today it has entered into an agreement and plan of merger with Swedish Orphan Biovitrum AB (Sobi) (OM:SOBI). Under the terms of the agreement, an indirect subsidiary of Sobi will commence a tender offer for all outstanding shares of Dova, whereby Dova stockholders will be offered an upfront payment for $27.50 per share in cash, along with one non-tradeable Contingent Value Right (CVR) that entitles them to an additional $1.50 per share in cash upon regulatory approval of DOPTELET for the treatment of chemotherapy-induced thrombocytopenia (CIT), representing a total potential consideration of $29.00 per share, or a total potential consideration of up to $915 million on a fully diluted basis.

Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi)

DURHAM, N.C., Sept.  25, 2019  (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 4:10 p.m. ET in New York, NY.

Dova Pharmaceuticals to Present at 2019 Cantor Global Healthcare Conference

Dova Pharmaceuticals (DOVA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Dova Pharmaceuticals (DOVA) Jumps: Stock Rises 8.8%

DURHAM, N.C., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President & Chief Executive Officer, will present company overviews at two upcoming investor conferences:

Dova Pharmaceuticals to Present at Upcoming Investor Conferences

Dova Pharmaceuticals, Inc. (DOVA) CEO David Zaccardelli on Q2 2019 Results - Earnings Call Transcript

Dova Pharmaceuticals (DOVA) delivered earnings and revenue surprises of -5.26% and -37.55%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Dova Pharmaceuticals (DOVA) Reports Q2 Loss, Lags Revenue Estimates

The company’s lead product is Doptelet (avatrombopag), an oral, thrombopoietin receptor agonist, which received FDA approval for treating refractory chronic idiopathic thrombocytopenia in adults.

Dova Pharmaceuticals: Analysis Of Doptelet's Potential In Various Thrombocytopenias

Dova Pharmaceuticals (DOVA) shares rose more than 9% in the last trading session, amid huge volumes.

Dova Pharmaceuticals (DOVA) in Focus: Stock Moves 9.1% Higher

Dova Pharmaceuticals obtained expanded FDA approval for Doptelet to treat adults with chronic immune thrombocytopenia.

News for Dova Pharma Stock (DOVA)